A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody-Anticalin Fusion) in Patients With Solid Tumors

Inclusion Criteria:

1. Age ≥18 years on the day the consent is signed.

2. Patients with histologically confirmed diagnosis of unresectable, locally advancedor metastatic solid tumor for which standard treatment options are not available, nolonger effective, or not tolerated.

3. Patient should have a documented disease progression on prior therapy before entryinto this study.

4. Patients must have at least one measurable target lesion as per RECIST 1.1.

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

6. Patient with no available archived material must have one or more tumor lesionsamenable to biopsy.

7. Adequate organ function as assessed by laboratory tests within 7 days prior topretreatment with obinutuzumab.

8. A female patient must use a highly effective method of birth control during studytreatment and for 120 days after last dose of PRS-344/S095012, or 18 months afterthe last obinutuzumab infusion, whichever comes the latest.

Exclusion Criteria:

1. Patients with previously treated brain metastases may participate provided they areradiologically stable, clinically asymptomatic and are off immunosuppressivetherapies for at least 4 weeks. Low dose of steroid <10 mg/day prednisone orequivalent) is allowed.

2. Patients who have received prior:

3. Small molecule inhibitors, and/or other similar investigational agent: ≤ 2weeks or 5 half-lives, whichever is shorter.

4. Chemotherapy, other monoclonal antibodies, antibody-drug conjugates, or othersimilar experimental therapies: ≤3 weeks or 5 half-lives, whichever is shorter.

5. Radioimmunoconjugates or other similar experimental therapies ≤6 weeks or 5half-lives, whichever is shorter.

6. Patients who have received 4-1BB agonists in the past.

7. Patients who had a major surgery within 4 weeks prior to first administration ofIMP.

8. History of progressive multifocal leukoencephalopathy.

9. Active tuberculosis requiring treatment within 3 years prior to the start oftreatment or a suspicion of latent tuberculosis by the investigator.